Pharmaceutical

CNS innovator oligonucleotide licensing value up 339% from £2bn in 2024

AbbVie, Lilly, Roche and Takeda have demonstrated strong interest in licensing innovator oligonucleotides for CNS indications.

Jun 21, 2025 - 06:00
CNS innovator oligonucleotide licensing value up 339% from £2bn in 2024
AbbVie, Lilly, Roche and Takeda have demonstrated strong interest in licensing innovator oligonucleotides for CNS indications.
Read the original article

Tags:

Previous Article

DoH – Abu Dhabi and Sanofi link for vaccine development

Next Article

UK and US governments pursue contrasting vaccine strategies

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Remembering Betty Rollin, who told her breast surgeon that post-operative appearance mattered to her—and other women

Opinion: Remembering Betty Rollin, who told her breast ...

Dec 27, 2023

Opinion: Dental care is in crisis. But it’s also a moment of opportunity

Opinion: Dental care is in crisis. But it’s also a mome...

Feb 13, 2024

Covid-19 vaccine confidence soured by officials’ messaging, Republicans argue

Covid-19 vaccine confidence soured by officials’ messag...

Feb 15, 2024